LongueVue Capital announced that its portfolio company, Summit Clinical Research, in partnership with its other portfolio company, Pinnacle Clinical Research, has completed a strategic investment in Houston Research Institute.
Houston Research Institute is a Houston, Texas-based clinical research site focused on Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease, cirrhosis, alcoholic liver disease and obesity.
Founded in 2018 and based in San Antonio, Texas, Summit Clinical Research is an integrated research organization specializing in complex indications. Summit specializes in complex clinical trials with a network of more than 120 sites.
Pinnacle Clinical Research is dedicated to conducting clinical trials in the areas of hepatology and gastroenterology, with a focus on fatty liver disease. The company is based in San Antonio, Texas.
In addition to the partnership with HRI, Summit added two key executives: Dr. Naim Alkhouri (Chief Academic Officer) and Brandon Early (President). Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the seventh clinical trial acquisition of 2025. Other acquirers in the specialty this year include Pratia, Flourish Research, Clario, The START Center for Cancer Research, BayPine and Voiant. There were 27 clinical trial transactions announced in 2024, and 42 announced in 2023.
